Alkermes PLC
Fechado
SetorSaúde
44.03 -0.32
Visão Geral
Variação de preço das ações
24h
Mín
43.4
Máximo
44.56
Rendimento | -116M -66M |
|---|---|
Vendas | 8.4M 393M |
P/E Médio do Setor | 47.167 49.052 |
EPS | 0.38 |
Margem de lucro | -16.92 |
Funcionários | 2,050 |
EBITDA | -98M -22M |
Recomendações | Compra Forte |
|---|---|
Previsão para 12 meses | +6.4% upside |
Próximos Ganhos | 28 de jul. de 2026 |
|---|
Capitalização de Mercado | 1.4B 7.1B |
|---|---|
Abertura anterior | 44.35 |
Fecho anterior | 44.03 |
Sentimento de Notícias
By Acuity
100%
0%
325 / 342 Ranking em Healthcare
Alkermes PLC Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Sobre Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
